查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2018083

植入式心臟整流去颤器市场：按产品类型、适应症、技术和最终用户划分－2026-2032年全球市场预测

Implantable Cardioverter Defibrillators Market by Product Type, Indication, Technology, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，植入式心臟整流去颤器(ICD) 市值将达到 50 亿美元，到 2026 年将成长至 52.8 亿美元，到 2032 年将达到 76.6 亿美元，复合年增长率为 6.28%。

主要市场统计数据
基准年 2025 50亿美元
预计年份：2026年 52.8亿美元
预测年份 2032 76.6亿美元
复合年增长率 (%) 6.28%

简要概述设备创新、不断发展的临床实践以及医疗保健系统面临的压力如何重塑 ICD 治疗的作用和提供方式。

植入式心臟整流去颤器（ICD）是现代心臟医学的基石，为有猝死风险的患者提供挽救生命的治疗。过去十年间，在材料科学、电池技术、感测演算法和通讯技术的推动下，ICD 的设计、植入技术和辅助监测都取得了显着进展。这些创新正在改变患者的选择、追踪模式和临床结果，同时也催生了电生理学、设备工程和数位健康之间的新交叉领域。

技术突破、不断发展的临床方案和医疗保健服务体系的变革如何从根本上重新定义 ICD 治疗和医疗保健提供者的优先事项。

由于技术、临床和系统性因素的共同作用，ICD治疗正经历变革性时期。小型化和皮下植入式设计降低了手术复杂性和器械相关感染疾病，而导线技术和感测演算法的进步提高了心律不整识别的准确性，并减少了不必要的治疗。除了硬体创新之外，软体改进和基于云端的远端监测也实现了长期数据收集，促进了预防性器械管理，并透过与远端保健的整合提高了患者的参与度。

本检验了近期关税政策和贸易趋势如何重塑整个 ICD 价值链的供应策略、成本压力和临床准入考量。

关税措施和贸易政策变化对植入式心臟装置（ICD）生态系统的累积影响，正为製造商、经销商和医疗保健系统带来新的挑战。关税波动影响半导体晶片、电池材料和电子子组件等上游组件的成本，进而影响筹资策略和供应商多元化。为此，製造商正在重新评估其采购地点并审查供应合同，以减轻贸易波动的成本影响。

将产品架构、临床适应症、底层技术和医疗保健环境与采用驱动因素和策略机会连结起来的详细細項分析。

细分市场分析表明，推动产品普及和临床效用的因素因产品类型、治疗适应症、底层技术和医疗环境而异。按产品类型划分，市场包括皮下植入式心臟復律去颤器 (ICD)、经静脉植入式心臟復律去颤器 (ICD) 和可穿戴式心臟復律去颤器 (ICD)，每种产品都满足不同的临床需求。皮下植入式系统优先考虑感染预防和减少血管内硬体；经静脉植入式装置提供起搏治疗和更先进的节律管理功能；穿戴式解决方案则在高风险时期提供临时保护或支援。按适应症划分，患者诊疗路径围绕一级和二级预防模式构建，决策演算法强调风险分层、合併症情况和预期寿命等因素，这些因素有助于确定植入的适用性和时机。

区域趋势和实施路径的差异凸显了报销制度、监管成熟度和医疗保健服务模式如何影响 ICD 的取得和采用。

区域趋势凸显了部署模式、报销环境和法规结构的多样性，这些因素共同塑造了各地区的ICD策略。在美洲，成熟的报销途径和高手术量与日益增长的成本控制和基于价值的采购理念并存，这要求器械供应商证明其产品具有相对疗效和长期性能。欧洲、中东和非洲（EMEA）地区则呈现出监管成熟度和医疗资金筹措模式的多元化格局，一些市场迅速采用MRI兼容性等先进功能，而另一些市场则优先考虑基本可及性和可负担性，因此需要差异化的市场准入和定价策略。

企业的关键竞争和策略趋势凸显了产品创新、伙伴关係、临床证据和供应链韧性等因素如何带来商业性优势。

植入式心臟復律去颤器 (ICD) 领域的竞争格局以持续投资于渐进式创新、策略伙伴关係和选择性整合为特征。老牌製造商不断投资新一代导线设计、电池化学和感测演算法，以延长设备寿命并减少不利事件。同时，新参与企业和中小企业则专注于穿戴式去心房颤动和以软体为中心的监测平台等细分创新，这些平台可与医疗管理系统整合。医疗设备製造商与数位医疗公司之间的策略合作正在迅速提升预测分析和远端监测仪錶板等功能，从而将价值主张从独立设备转向完整的医疗解决方案套件。

制定切实可行的策略重点，协调临床证据产生、产品设计和供应链敏捷性，加快部署速度，并维持商业性韧性。

产业领导者应采取整合策略，将产品开发、临床证据策略和供应链韧性结合，以确保永续的竞争优势。优先投资于能够显着降低手术併发症并改善患者体验的技术，同时确保临床试验和註册研究的设计能够捕捉到对支付方和医疗服务提供者至关重要的终点指标。此外，还应实现筹资策略多元化，并考虑区域组装和契约製造，以降低关税和贸易政策波动带来的风险，同时确保产品品质和合规性。

透过结合专家访谈和系统的二手文献综述，调查方法，确保了可靠和实用的知识。

本报告的研究结合了对临床和商业专家的定性访谈和对同行评审文献、监管文件和临床试验註册资讯的整合，以确保观点平衡且基于证据。主要研究包括对电生理学家、医疗设备诊所经理、采购负责人和供应链负责人的访谈，以了解真实的临床实践模式和决策标准。此外，还系统地审查了包括技术评估、安全性概况和比较分析第二手资料，以从多方面检验研究结果，并支持每个主题的研究结论。

一份简洁、全面的分析报告，阐述了创新、证据和营运准备的策略平衡，这对于负责任且有效地推进 ICD 治疗至关重要。

植入式心臟整流去颤器（ICD）领域正处于一个转折点，其特点是技术取得了显着进步，医疗服务模式发生了转变，同时供应炼和政策风险也日益受到关注。设备设计和远端功能的进步为改善患者预后和简化追踪流程提供了明确的机会，但要实现这些益处，需要持续的证据支持、灵活的商业策略和稳健的营运系统。能够积极将临床需求与可操作的服务模式结合的医疗系统和製造商，最有能力在控製成本和应对准入压力的同时，创造价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：植入式心臟整流去颤器市场：依产品类型划分

  • 皮下植入式心臟復律去颤器
  • 经静脉植入式心律转復除颤器
  • 穿戴式植入式心律转復除颤器

第九章：植入式心臟整流去颤器市场：依适应症划分

  • 第一级预防
  • 二级预防

第十章：植入式心臟整流去颤器市场：依技术划分

  • 与核磁共振相容
  • 远端监控支援

第十一章：植入式心臟整流去颤器市场：依最终用户划分

  • 门诊手术中心
  • 心臟护理中心
  • 诊所
  • 医院

第十二章：植入式心臟整流去颤器市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：植入式心臟整流去颤器市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：植入式心臟整流去颤器市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国植入式心臟整流去颤器市场

第十六章：中国植入式心臟整流去颤器市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Angiplast Pvt Ltd.
  • Atrium Medical, Inc.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • ConMed Corporation
  • ConvaTec Group PLC
  • Cook Medical Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Getinge AB
  • Kestra Medical Technologies Inc.
  • Lepu Medical Technology Co., Ltd.
  • LivaNova PLC
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • MicroPort Scientific Corporation
  • Olympus Corporation
  • Penumbra, Inc.
  • Romsons Group
  • Shandong Weigao Group Medical Polymer Co., Ltd.
  • Smiths Medical PM Inc.
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Corporation
  • Vygon SA
  • ZOLL Medical Corporation
Product Code: MRR-037F3DB25943

The Implantable Cardioverter Defibrillators Market was valued at USD 5.00 billion in 2025 and is projected to grow to USD 5.28 billion in 2026, with a CAGR of 6.28%, reaching USD 7.66 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.00 billion
Estimated Year [2026] USD 5.28 billion
Forecast Year [2032] USD 7.66 billion
CAGR (%) 6.28%

A concise framing of how device innovation, evolving clinical practice, and health system pressures are reshaping the role and delivery of ICD therapy

Implantable cardioverter defibrillators (ICDs) are a cornerstone of modern cardiac care, providing life-saving therapy to patients at risk of sudden cardiac death. Over the past decade, device design, implantation techniques, and adjunctive monitoring have evolved significantly, driven by advances in materials science, battery technology, sensing algorithms, and remote connectivity. These innovations have reshaped patient selection, follow-up paradigms, and clinical outcomes, while creating new intersections between electrophysiology, device engineering, and digital health.

As the clinical landscape becomes more complex, stakeholders across hospitals, clinics, and ambulatory surgical centers must reconcile evolving evidence with operational realities. The interplay between primary and secondary prevention indications has become more nuanced, with refined risk stratification informing who benefits most from implantation. Concurrently, technology shifts such as MRI compatibility and remote monitoring have expanded device utility, but also introduced new considerations for device longevity, interoperability, and data governance. The resulting environment requires decision-makers to balance clinical efficacy, patient safety, and economic sustainability while navigating regulatory and reimbursement dynamics.

How converging technological breakthroughs, evolving clinical protocols, and care delivery shifts are fundamentally redefining ICD therapy and provider priorities

ICD therapy is undergoing a period of transformative change driven by converging technological, clinical, and system-level forces. Miniaturization and subcutaneous designs are reducing procedural complexity and device-related infections, while advances in lead technology and sensing algorithms improve arrhythmia discrimination and reduce inappropriate therapy. Parallel to hardware innovation, software enhancements and cloud-enabled remote monitoring are enabling longitudinal data capture, facilitating proactive device management, and enhancing patient engagement through telehealth integrations.

Regulatory frameworks and clinical pathways are adapting to these advances, accelerating pathways for MRI-compatible systems and devices with enhanced remote capabilities, but also raising the bar for real-world evidence and long-term safety data. Health systems are responding by evolving care models; ambulatory surgical centers are increasingly performing elective ICD implants, while hospitals and specialized cardiac centers retain complex cases. Collectively, these shifts are changing procurement priorities, clinical workflows, and value assessments, demanding integrated strategies that align product design with the operational realities of contemporary cardiac care.

Examining how recent tariff policies and trade dynamics have reshaped supply strategies, cost pressures, and clinical access considerations across the ICD value chain

The cumulative impact of tariff actions and trade policy changes on the ICD ecosystem has introduced new layers of complexity for manufacturers, distributors, and health systems. Tariff fluctuations affect upstream component costs, including semiconductor chips, battery materials, and electronic subassemblies, thereby influencing procurement strategies and supplier diversification. In response, manufacturers are reassessing sourcing footprints and reevaluating supply contracts to mitigate exposure to trade-driven cost variability.

Downstream, hospitals and ambulatory surgical centers face pressure to preserve budgetary flexibility while maintaining access to the latest device technologies. The tension between cost containment and clinical necessity has prompted greater scrutiny of total cost of ownership, spare parts inventories, and lead times. In some cases, manufacturers are accelerating plans for regional manufacturing or localized assembly to reduce tariff impact and strengthen just-in-time delivery capabilities. These strategic shifts are accompanied by closer collaboration between commercial teams and clinical stakeholders to prioritize device allocations based on clinical urgency and outcome expectations. Ultimately, trade policy changes are not uniform in effect; their cumulative impact is mediated by contract structures, regulatory requirements, and the agility of supply chain strategies implemented by device makers and health systems alike.

Deep segmentation insights that connect product architecture, clinical indication, enabling technologies, and care settings to adoption drivers and strategic opportunities

Segmentation analysis reveals differentiated drivers of adoption and clinical utility across product types, therapeutic indications, enabling technologies, and care settings. Based on Product Type, the landscape includes Subcutaneous ICDs, Transvenous ICDs, and Wearable ICDs, each addressing distinct clinical needs: subcutaneous systems prioritize infection avoidance and reduced intravascular hardware, transvenous devices offer pacing therapies and deeper rhythm management capabilities, while wearable solutions serve as interim protection or as adjuncts for high-risk periods. Based on Indication, patient pathways are framed by Primary Prevention and Secondary Prevention paradigms, with decision algorithms emphasizing risk stratification, comorbidity profiles, and life expectancy considerations that inform candidacy and timing for implantation.

Based on Technology, MRI Compatible and Remote Monitoring Enabled devices redefine post-implant care and diagnostic confidence, as MRI compatibility reduces barriers to advanced imaging and remote monitoring supports proactive device management and early detection of complications. Based on End User, Ambulatory Surgical Centers, Cardiac Care Centers, Clinics, and Hospitals embody different procedural volumes, case complexity, and infrastructure capacities, which in turn influence purchasing criteria, service agreements, and clinical support needs. Understanding these intersecting segment dynamics is essential for targeting innovation efforts, designing differentiated commercial propositions, and aligning clinical training and support services with the environments where devices are implanted and managed.

Regional dynamics and differentiated adoption pathways that illuminate how reimbursement, regulatory maturity, and care delivery models shape ICD access and deployment

Regional dynamics underscore heterogeneous adoption patterns, reimbursement environments, and regulatory frameworks that shape ICD strategy by geography. In the Americas, established reimbursement pathways and high procedural volumes coexist with growing emphasis on cost containment and value-based procurement, prompting device providers to demonstrate comparative effectiveness and long-term performance. The Europe, Middle East & Africa region presents a mosaic of regulatory maturity and healthcare funding models, where some markets rapidly adopt advanced features such as MRI compatibility while others prioritize basic access and affordability, thus requiring differentiated market entry and pricing approaches.

In the Asia-Pacific region, rapid investment in cardiac infrastructure and increasing uptake of minimally invasive techniques are expanding indications for device therapy, but market heterogeneity remains pronounced across public and private systems. Across all regions, regional clinical networks, investigator-led registries, and local guidelines influence adoption curves and post-market evidence requirements. Manufacturers and health systems that tailor value propositions to regional nuances-balancing clinical performance, service models, and pricing-can better navigate reimbursement complexities and accelerate responsible access to device therapy.

Key competitive and strategic company trends highlighting where product innovation, partnerships, clinical evidence, and supply resilience create commercial advantage

Competitive dynamics in the ICD space are characterized by sustained investment in incremental innovation, strategic partnerships, and selective consolidation. Established manufacturers continue to invest in next-generation lead designs, battery chemistries, and sensing algorithms to extend device longevity and reduce adverse events, while newer entrants and smaller firms are focusing on niche innovations such as wearable defibrillators and software-centric monitoring platforms that integrate with care management systems. Strategic collaborations between device companies and digital health firms are accelerating features like predictive analytics and remote monitoring dashboards, which can shift value conversations from device alone to bundled care solutions.

At the same time, intellectual property portfolios and clinical evidence generation remain pivotal competitive levers; firms that can demonstrate long-term safety and real-world effectiveness through registries and post-market studies gain negotiating power with payers and procurement teams. Supply chain resilience and manufacturing flexibility also differentiate competitors, particularly in a climate where trade policy and component scarcity can affect availability. For commercial teams, the competitive imperative is to align product roadmaps with service offerings and clinical support that address the full lifecycle of device use from implantation through long-term follow-up.

Practical strategic priorities that align clinical evidence generation, product design, and supply chain agility to accelerate adoption and preserve commercial resilience

Industry leaders should adopt an integrated approach that aligns product development, clinical evidence strategies, and supply chain resilience to secure sustainable advantage. Prioritize investments in technologies that demonstrably reduce procedural complications and improve patient experience, while ensuring that clinical trials and registries are designed to capture endpoints that matter to payers and providers. Concurrently, diversify sourcing strategies and consider regional assembly or contract manufacturing to mitigate exposure to tariff and trade policy volatility while maintaining quality and regulatory compliance.

Commercial strategies should emphasize bundled value propositions that combine devices with remote monitoring services and clinician support, enabling clearer demonstrations of outcome improvements and total cost implications for health systems. Strengthen collaboration with centers of excellence and clinician champions to accelerate uptake and to co-create training programs that lower the barrier to adoption in ambulatory settings. Finally, invest in data interoperability and cybersecurity measures to ensure that remote monitoring and device data can be integrated into electronic health records and care pathways securely, thereby increasing clinician trust and patient acceptance.

A transparent, clinician-informed research methodology combining expert interviews and systematic secondary review to ensure robust, actionable insights

The research underpinning this report combined primary qualitative engagement with clinical and commercial experts and secondary synthesis of peer-reviewed literature, regulatory filings, and clinical trial registries to ensure a balanced and evidence-based perspective. Primary engagements included interviews with electrophysiologists, device clinic managers, procurement professionals, and supply chain leaders to capture real-world practice patterns and decision criteria. Secondary sources were systematically reviewed for technology assessments, safety profiles, and comparative analyses to triangulate insights and validate thematic findings.

Analytical rigor was maintained through cross-validation of interview findings against published clinical guidelines and regulatory approvals. Limitations were acknowledged where high-quality long-term data are still emerging, particularly for newer subcutaneous and wearable solutions. The methodology emphasized transparency in source attribution and applied qualitative synthesis to translate heterogeneous data into actionable implications for stakeholders. Quality assurance processes included internal peer review and methodological checks to reduce bias and ensure the relevance of conclusions for commercial and clinical decision-making.

A concise synthesis capturing the strategic balance of innovation, evidence, and operational readiness required to advance ICD therapy responsibly and effectively

The implantable cardioverter defibrillator landscape is at an inflection point characterized by meaningful technological progress, shifting care delivery models, and heightened attention to supply chain and policy risks. Advances in device design and remote capabilities offer clear opportunities to improve patient outcomes and streamline follow-up, yet realizing these benefits requires aligned evidence generation, adaptable commercial strategies, and resilient operations. Health systems and manufacturers that proactively bridge clinical needs with pragmatic service models will be best positioned to deliver value while managing cost and access pressures.

Looking ahead, the successful commercialization of ICD innovations will depend on credible long-term safety data, interoperable digital ecosystems, and partnerships that integrate devices into broader care pathways. By focusing on these priorities, stakeholders can navigate regulatory complexity, address payer expectations, and expand responsible access to life-saving therapy across diverse healthcare environments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Implantable Cardioverter Defibrillators Market, by Product Type

  • 8.1. Subcutaneous ICDs
  • 8.2. Transvenous ICDs
  • 8.3. Wearable ICDs

9. Implantable Cardioverter Defibrillators Market, by Indication

  • 9.1. Primary Prevention
  • 9.2. Secondary Prevention

10. Implantable Cardioverter Defibrillators Market, by Technology

  • 10.1. MRI Compatible
  • 10.2. Remote Monitoring Enabled

11. Implantable Cardioverter Defibrillators Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cardiac Care Centers
  • 11.3. Clinics
  • 11.4. Hospitals

12. Implantable Cardioverter Defibrillators Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Implantable Cardioverter Defibrillators Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Implantable Cardioverter Defibrillators Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Implantable Cardioverter Defibrillators Market

16. China Implantable Cardioverter Defibrillators Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Angiplast Pvt Ltd.
  • 17.7. Atrium Medical, Inc.
  • 17.8. B. Braun Melsungen AG
  • 17.9. Baxter International Inc.
  • 17.10. Becton, Dickinson and Company
  • 17.11. BIOTRONIK SE & Co. KG
  • 17.12. Boston Scientific Corporation
  • 17.13. Cardinal Health, Inc.
  • 17.14. ConMed Corporation
  • 17.15. ConvaTec Group PLC
  • 17.16. Cook Medical Inc.
  • 17.17. Fresenius Medical Care AG & Co. KGaA
  • 17.18. Getinge AB
  • 17.19. Kestra Medical Technologies Inc.
  • 17.20. Lepu Medical Technology Co., Ltd.
  • 17.21. LivaNova PLC
  • 17.22. Medtronic plc
  • 17.23. Merit Medical Systems, Inc.
  • 17.24. MicroPort Scientific Corporation
  • 17.25. Olympus Corporation
  • 17.26. Penumbra, Inc.
  • 17.27. Romsons Group
  • 17.28. Shandong Weigao Group Medical Polymer Co., Ltd.
  • 17.29. Smiths Medical PM Inc.
  • 17.30. Stryker Corporation
  • 17.31. Teleflex Incorporated
  • 17.32. Terumo Corporation
  • 17.33. Vygon SA
  • 17.34. ZOLL Medical Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY SUBCUTANEOUS ICDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY SUBCUTANEOUS ICDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY SUBCUTANEOUS ICDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TRANSVENOUS ICDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TRANSVENOUS ICDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TRANSVENOUS ICDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY WEARABLE ICDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY WEARABLE ICDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY WEARABLE ICDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRIMARY PREVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRIMARY PREVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRIMARY PREVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY SECONDARY PREVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY SECONDARY PREVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY SECONDARY PREVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY MRI COMPATIBLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY MRI COMPATIBLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY MRI COMPATIBLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY REMOTE MONITORING ENABLED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY REMOTE MONITORING ENABLED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY REMOTE MONITORING ENABLED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY CARDIAC CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY CARDIAC CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY CARDIAC CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. LATIN AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. MIDDLE EAST IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. ASEAN IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GCC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GCC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. GCC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. GCC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. GCC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPEAN UNION IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. BRICS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. G7 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. G7 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. G7 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. G7 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. G7 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NATO IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. NATO IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NATO IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. NATO IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. NATO IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. UNITED STATES IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. CHINA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)